NFKB1 and neoplasm: As shown in Figure 4, in vitro experimental results suggest that FX can inhibit inflammatory imbalance and reduce tumor-induced lymph angiogenesis in human breast cancer MDA-MB-231 cells [22] by decreasing the expression levels of p-PI3K, p-Akt, NF-κB, VEGF-C, and VEGF receptor-3 in human lymphatic endothelial cells, thereby inhibiting breast cancer cells through the regulation of inflammation.